Xoma Technology Ltd.

Xoma (us) Technology Ltd.

Jong-Jye Lin

Roger G Little, Ii

J G Kinyua Gikonyo

The present invention relates generally to small peptide-based constructs, including derivatized constructs, and their therapeutic uses. The constructs and derivatized constructs can have at least one of heparin binding, heparin neutralizing, endothelial cell proliferation inhibiting, antiangiogenic, LPS binding, LPS neutralization, or antimicrobial properties. The sequences of these constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).

Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein

The present invention relates generally to small peptide-based constructs and their therapeutic uses. The sequences of these peptide-based constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).

Therapeutic peptide-based constructs

Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein

The present invention relates generally to small derivatized peptide-based constructs and their therapeutic uses. The sequences of these derivatized peptide-based constructs are based on a reverse subsequence derived from Domain II of bactericidal/permeability-increasing protein (BPI).

Therapeutic derivative compounds derived from domain II of bactericidal/permeability-increasing protein

The present invention relates generally to derivatized antifungal compounds that are peptide-based constructs derived from or based on subsequences of Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such compounds.

Growing community of inventors

Hercules, CA, United States of America

Jong-Jye Lin